Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Intra-Cellular Therapies (ITCI) Stock Forecast & Price Target

Intra-Cellular Therapies logo
Get the Latest News and Ratings for ITCI and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Intra-Cellular Therapies and its competitors.

Sign Up

ITCI Analyst Ratings Over Time

TypeCurrent Forecast
7/24/24 to 7/24/25
1 Month Ago
6/24/24 to 6/24/25
3 Months Ago
4/25/24 to 4/25/25
1 Year Ago
7/25/23 to 7/24/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
10 Buy rating(s)
Hold
10 Hold rating(s)
10 Hold rating(s)
10 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$109.70$109.70$109.70$94.83
Forecasted Upside-16.81% Downside-16.81% Downside-16.81% Downside22.73% Upside
Consensus Rating
Hold
Hold
Hold
Moderate Buy

ITCI Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ITCI Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Intra-Cellular Therapies Stock vs. The Competition

TypeIntra-Cellular TherapiesMedical CompaniesS&P 500
Consensus Rating Score
2.17
2.81
2.53
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside-16.81% Downside8,234.61% Upside9.38% Upside
News Sentiment Rating
Neutral News

See Recent ITCI News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/2/2025Cantor Fitzgerald
4 of 5 stars
C. Duncan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$132.00 ➝ $132.00+0.07%
2/24/2025Mizuho
3 of 5 stars
Graig Suvannavejh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral$140.00 ➝ $132.00+2.64%
2/21/2025Needham & Company LLC
2 of 5 stars
A. Fadia
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
1/31/2025Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Sumant Kulkarni
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$119.00 ➝ $132.00+3.94%
1/22/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Brian Abrahams
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Sector Perform$108.00 ➝ $132.00+3.61%
1/14/2025Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
David Amsellem
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Neutral$107.00 ➝ $132.00+3.89%
1/13/2025Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Goodman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
1/13/2025Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Beatty
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
11/4/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$81.00 ➝ $89.00+2.84%
10/11/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$92.00 ➝ $95.00+25.02%
8/8/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Verma
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$83.00 ➝ $79.00+7.61%
8/8/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$77.00 ➝ $74.00+0.50%
4/17/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$80.00 ➝ $90.00+15.05%
4/17/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$83.00 ➝ $103.00+31.66%
4/17/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$82.00 ➝ $91.00+16.32%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 06:25 AM ET.


ITCI Forecast - Frequently Asked Questions

According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Intra-Cellular Therapies is $109.70, with a high forecast of $132.00 and a low forecast of $74.00.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last twelve months. There are currently 10 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ITCI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ITCI, but not buy additional shares or sell existing shares.

According to analysts, Intra-Cellular Therapies's stock has a predicted downside of -16.81% based on their 12-month stock forecasts.

Analysts like Intra-Cellular Therapies less than other "medical" companies. The consensus rating for Intra-Cellular Therapies is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ITCI compares to other companies.


This page (NASDAQ:ITCI) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners